Pub. Date : 2004
PMID : 15005635
7 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteers. | Nateglinide | cytochrome P450 family 2 subfamily C member 9 | Homo sapiens |
| 2 | According to in vitro data, about 70% of nateglinide intrinsic clearance may be mediated by cytochrome P450 (CYP) 2C9 and a smaller fraction by CYP3A4 and CYP2D6. | Nateglinide | cytochrome P450 family 2 subfamily C member 9 | Homo sapiens |
| 3 | RESULTS: Significantly reduced oral nateglinide clearance was found in carriers of CYP2C9*3 alleles, (p < 0.01), whereas carriers of CYP2C9*2 alleles had kinetic parameters similar to those of carriers of the wild-type allele (p = nonsignificant). | Nateglinide | cytochrome P450 family 2 subfamily C member 9 | Homo sapiens |
| 4 | These differences in nateglinide kinetics due to CYP2C9 genotypes did not result in statistically significant differences in plasma glucose, insulin and glucagon. | Nateglinide | cytochrome P450 family 2 subfamily C member 9 | Homo sapiens |
| 5 | Pharmacokinetic-pharmacodynamic modelling revealed a minor effect of CYP2C9 genotype on insulin and glucose, and extrapolations indicated that carriers of the CYP2C9*3/*3 genotype may be at a slightly higher risk of hypoglycaemia compared with carriers of CYP2C9*1, particularly when taking nateglinide doses above 120 mg. | Nateglinide | cytochrome P450 family 2 subfamily C member 9 | Homo sapiens |
| 6 | Pharmacokinetic-pharmacodynamic modelling revealed a minor effect of CYP2C9 genotype on insulin and glucose, and extrapolations indicated that carriers of the CYP2C9*3/*3 genotype may be at a slightly higher risk of hypoglycaemia compared with carriers of CYP2C9*1, particularly when taking nateglinide doses above 120 mg. | Nateglinide | cytochrome P450 family 2 subfamily C member 9 | Homo sapiens |
| 7 | CONCLUSION: The effect of CYP2C9 polymorphisms on nateglinide kinetics may cause a slightly increased risk for hypoglycaemia, which may become relevant in diabetic patients. | Nateglinide | cytochrome P450 family 2 subfamily C member 9 | Homo sapiens |